Welcome to our dedicated page for Infusystem Hld news (Ticker: INFU), a resource for investors and traders seeking the latest updates and insights on Infusystem Hld stock.
InfuSystem Holdings, Inc. (NYSE American: INFU) regularly issues news and press releases that are of interest to investors, analysts and others following the health care services and durable medical equipment space. The company describes itself as a national health care service provider that facilitates outpatient care for durable medical equipment manufacturers and health care providers, with operations organized into Patient Services and Device Solutions platforms.
News items about InfuSystem often include quarterly and annual financial results, where the company discusses net revenues, segment performance for Patient Services and Device Solutions, gross margin trends, cash flow, and Adjusted EBITDA. These releases typically highlight how oncology, pain management and wound therapy within Patient Services, as well as rentals, pump and consumable sales, and biomedical services within Device Solutions, have contributed to overall results.
Another common category of news involves guidance and outlook. InfuSystem has used press releases to provide or reaffirm guidance ranges for net revenue growth and Adjusted EBITDA margin for upcoming fiscal years, and to explain how factors such as revenue mix, information technology projects, and capital expenditures may affect margins and cash flow.
The company also issues announcements about leadership changes and corporate governance, such as the CEO transition disclosed in April 2025, and about participation in investor conferences hosted by firms like ROTH and Craig-Hallum. These items often note that management will host one-on-one or small group meetings with investors.
In addition, InfuSystem uses news releases to communicate regulatory and policy developments that affect its business. For example, an 8-K dated December 10, 2025 references a press release announcing that the Centers for Medicare and Medicaid Services added two electronic infusion pumps used in the company’s Pain Management services business to the list of qualifying products for separate payment under the NOPAIN Act.
Visitors to the INFU news page can review this stream of financial updates, guidance, leadership announcements, conference participation notices and regulatory disclosures to understand how the company describes its performance and strategic priorities over time.
InfuSystem Holdings (NYSE American: INFU) announced it will release its preliminary fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025, before market opening. The company will host an investor conference call at 9:00 a.m. Eastern Time on the same day to discuss the results.
Interested parties can participate in the call by dialing (833) 366-1127 or (412) 902-6773, or listen via a live webcast available in the Investors section of the company's website. A replay will be accessible for 90 days on the company's website or by calling (877) 344-7529 or (412) 317-0088 with replay access code 9301008 through March 11, 2025.
InfuSystem is a national healthcare service provider operating under a two-platform model: Patient Services (offering last-mile solutions for clinic-to-home healthcare) and Device Solutions (supporting Patient Services with direct payer rentals, pump and consumable sales, and biomedical services).
Sidoti Events, has announced its December Small-Cap Conference schedule for December 4-5, 2024. The two-day virtual event features presentations from numerous publicly traded companies, including Charles River Associates (CRAI) scheduled for 10:45-11:15 EST on December 4th. The conference includes a mix of company presentations and one-on-one meetings with various small-cap companies across different sectors. The presentation schedule is subject to change, and attendees are directed to www.sidoti.com/events for the most current schedule and webinar links.
InfuSystem Holdings (NYSE American: INFU) announced its participation in the upcoming Sidoti Small Cap Virtual Investor Conference on December 4, 2024. The company's leadership team, including CEO Richard DiIorio, CFO Barry Steele, and President/COO Carrie Lachance, will present at 10:00 a.m. ET.
The presentation will be available via webcast on the company's investor relations website, with a replay option available post-event. Management will also host one-on-one meetings throughout the day. InfuSystem operates under two platforms: Patient Services (providing clinic-to-home healthcare solutions) and Device Solutions (supporting direct payer clients with rentals, sales, and biomedical services).
InfuSystem Holdings (NYSE American: INFU) has appointed Ronald Hundzinski as an independent director to its Board of Directors, effective November 12, 2024. Hundzinski, who will serve until the next Annual Shareholders meeting in May 2025, brings significant financial expertise and operational experience. He currently serves as Chairman of Gentherm's Board of Directors and previously held CFO positions at TI Fluid Systems, Tenneco Inc., and BorgWarner. The appointment strengthens InfuSystem's board oversight with his extensive accounting, finance, and operational expertise in healthcare services.
InfuSystem Holdings reported strong Q3 2024 financial results with record net revenues of $35.3 million, up 11% year-over-year. Net income increased 162% to $1.8 million ($0.08 per diluted share). Patient Services revenue grew 8% to $20.8 million, while Device Solutions revenue rose 15% to $14.5 million. The company's gross margin improved to 53.9%, up 5.0%. Adjusted EBITDA reached $7.9 million, increasing 27% with margin expansion to 22.3%. Operating cash flow surged 91% to $12.5 million. The company entered new strategic partnerships with Smith+Nephew for wound therapy and became exclusive distributor of Chemo Mouthpiece® through SI Healthcare Technologies joint venture.
InfuSystem Holdings (NYSE American: INFU) announced it will release its third quarter 2024 financial results on November 7, 2024, before market open. The company will host a conference call at 9:00 a.m. Eastern Time on the same day to discuss the results. InfuSystem operates through two platforms: Patient Services, providing clinic-to-home healthcare solutions for complex medical equipment, and Device Solutions, supporting direct payer clients with rentals, sales, and biomedical services.
InfuSystem Holdings, Inc. (NYSE American: INFU) announced its participation in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024. Key executives, including CEO Richard DiIorio, President and COO Carrie Lachance, and CFO Barry Steele, will be present. A webcasted fireside chat with DiIorio is scheduled for 3:30pm ET.
The webcast will be accessible via the conference website and InfuSystem's investor relations page. Management will be available for one-on-one and group meetings with investors. InfuSystem is a leading national health care service provider operating under two platforms: Patient Services and Device Solutions. The company facilitates outpatient care for durable medical equipment manufacturers and health care providers, with a focus on oncology, pain management, and wound therapy.
InfuSystem Holdings (NYSE American: INFU) and Sanara MedTech have announced an exclusive U.S. distribution agreement with ChemoMouthpiece, Their joint venture, SI Healthcare Technologies, will distribute ChemoMouthpiece's FDA-cleared oral cryotherapy device to approximately 3,000 cancer centers through InfuSystem's Oncology sales team.
The device aims to reduce oral mucositis in patients undergoing chemotherapy. Sanara invested $5 million for a 6.6% ownership in ChemoMouthpiece. The U.S. market for oral mucositis treatment is estimated at over $600 million annually, affecting 500,000 to 1 million patients. The American Medical Association has issued a CPT code (effective July 2024) for potential reimbursement of oral cavity cryotherapy devices used with chemotherapy.
InfuSystem Holdings (NYSE American: INFU) announced its participation in Lake Street Capital Markets' 8th Annual Best Ideas Growth (BIG8) Conference on September 12, 2024, at The Yale Club in New York City. CEO Richard DiIorio and CFO Barry Steele will be available for one-on-one and group meetings with investors throughout the day.
InfuSystem is a leading national health care service provider facilitating outpatient care for durable medical equipment manufacturers and health care providers. The company operates under two platforms: Patient Services (Oncology, Pain Management, and Wound Therapy) and Device Solutions (direct payer rentals, pump and consumable sales, and biomedical services).
Headquartered in Rochester Hills, Michigan, InfuSystem delivers local, field-based customer support and operates Centers of Excellence across the United States and Canada.
InfuSystem Holdings (NYSE American:INFU) reported strong Q2 2024 financial results, with record net revenues of $33.7 million, up 6% year-over-year. Key highlights include:
- Patient Services revenue increased 5% to $20.2 million
- Device Solutions revenue grew 8% to $13.5 million
- Net income rose 64.8% to $0.7 million, or $0.03 per diluted share
- Adjusted EBITDA increased 5% to $6.1 million
- Net operating cash flow up 17% to $2.7 million
The company reaffirmed its full-year 2024 guidance, projecting high-single-digit revenue growth and Adjusted EBITDA margin in the high-teens. InfuSystem's CEO highlighted the company's strategic partnerships and diversification efforts, including a new distribution agreement with Smith+Nephew.
FAQ
What is the current stock price of Infusystem Hld (INFU)?
What is the market cap of Infusystem Hld (INFU)?
